Immune cells, checkpoints, and tumor antigens jointly set the strength of anti-tumor responses.
AblyBio · Research Areas
癌症
Cancer research centers on the molecular drivers of tumorigenesis, progression, immune evasion, and therapy resistance. AblyBio provides high-specificity antibodies across tumor immunology, biomarkers, suppressors, drug resistance, and invasion/metastasis for basic and translational studies.
Immune cells, checkpoints, and tumor antigens jointly set the strength of anti-tumor responses.
Diagnostic/prognostic markers and suppressor pathways such as p53 are central to classification and mechanism.
Efflux pumps, topoisomerases, and invasion proteins illuminate therapy failure and distant spread.
Mechanistic highlights and entry points for your research
Cancer arises from genomic instability, epigenetic disruption, and microenvironmental cues. Loss of tumor suppressors, oncogene activation, checkpoint dysregulation, and extracellular-matrix remodeling drive growth, angiogenesis, and distant metastasis.
Precise detection of tumor-associated antigens, pathway nodes, and resistance proteins helps clarify mechanisms, nominate biomarkers, and evaluate targeted and immuno-oncology strategies.
Use the topic links below to enter tumor immunology, biomarkers, drug resistance, or invasion/metastasis and find matching antibodies.
Drill into mechanisms and targets to find matching antibodies
Validated antibodies for this research area across WB, IHC, IF and more
966 products